Covid-19 Vaccinations: 12 to 15-year-olds

Philippa Whitford Excerpts

Monday 13th September 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful to my right hon. Friend for his important question. He is right to identify that this is a sensitive issue, which is why it was right for the Joint Committee on Vaccination and Immunisation to take its time to look at the data from other countries on first doses and second doses and for the chief medical officers to then do the work unimpeded which they needed to do. It is right that we follow their advice tonight.

On the booster campaign, we have received the interim advice from the Joint Committee on Vaccination and Immunisation—it was published on 30 June this year— on a potential booster programme, including flu and covid vaccine. I can reassure my right hon. Friend that the decision on Valneva will not impact our booster vaccination programme. We await the final advice. The JCVI has received the data from the COV-Boost study, where we looked at all the different vaccine brands—in some instances, full doses and half doses—as to which is the best vaccine to boost with.

I assure him that later this month we will begin a major booster programme. On flu—of course, the flu programme has already begun, and I assure him that we have the supplies for a major programme for both—we are looking at the really ambitious number of 35 million and, when we get the final advice from JCVI, the booster programme will be equally ambitious.

[Dr Philippa Whitford (Central Ayrshire) (SNP)]

I, too, welcome the decision to vaccinate 12 to 15-year-olds. Scotland’s NHS is also primed to deliver vaccinations as quickly as possible, but it is a pity that there was a delay and that the opportunity to vaccinate during the summer holidays was missed. In Scotland, where our schools went back before English schools, we have seen a huge surge, and we are seeing the same rise in Northern Ireland and Wales. That may happen here as well. I wonder how much of the delay was down to the remit given to the JCVI, which seemed to focus on hospitalisation and death—quite rare, thankfully, among children—rather than considering the wider impacts of education and socialisation loss or of long covid, which we are seeing in young people and children. Was the delay about the remit? Was the JCVI given a narrow remit? Or was it about whether Pfizer and Moderna vaccines would be sufficient to allow the group to have been vaccinated in the summer?

There are rumours that there will be a U-turn tonight on yesterday’s U-turn on vaccine passports. I would be grateful for the Minister clarifying that. Whether that is the case or not, this chaos undermines public health messaging, creates confusion among the public and creates rejection of whatever decision finally comes.

[Nadhim Zahawi]

The hon. Lady asked a number of questions that I will try to address in order. She asked about the JCVI’s remit, which was very much around what it is clinically qualified to address. That is why it advised that the CMOs needed to look at the wider impact on children specifically. There was no issue at all around shortage of vaccines, and I am confident that we have the vaccine supply that we need for both this recommendation, which we are accepting, and the booster campaign.

It was important that the JCVI took its time and looked at both first-dose and second-dose data on the rare signal around myocarditis and pericarditis. The United Kingdom has sometimes been an outlier to other nations, but on the whole we have got these decisions right because we rely on that expert clinical advice. I hope that gives reassurance to families up and down the country.

On vaccine passports, the Secretary of State for Health made it clear that we will not go ahead with vaccine certification for nightclubs or other venues. No one—certainly not on the Government side—would have moved forward with that happily. [Interruption.] If we are to have a grown-up debate, it is important for the whole House to remember that the virus is still with us and that we all want the same thing: to transition it from pandemic to endemic status so that we can have a sustainable return to normality as quickly as possible.